Drug Trial Radar · NCT05997615
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
347
Planned (sponsor's estimate)
Start
Aug 10, 2023
Primary completion
Sep 30, 2027
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Vir Biotechnology, Inc.
- First posted
- Aug 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment. This is an early development study of VIR-5500 in men with prostate cancer. In this study, VIR-5500 will be given to people for the first time. VIR-5500 will either be given by itself or given together with one or more standard cancer treatments: enzalutamide, darolutamide and docetaxel. Some other cancer treatments may also be given with VIR-5500 during this study, depending on results from other ongoing studies. Early development studies are mostly about safety, but also to find the most suitable dose. Other aims are to check if VIR-5500 shows signs of reducing tumor growth and to learn how the body processes VIR-5500. This will be done both for VIR-5500 given by itself and given together with the other cancer treatments. The main aim(s) of the study are to check the safety of different doses of VIR-5500 when given by itself and given together with the standard cancer treatments, and how well it is tolerated; to find a suitable dose of VIR-5500 when given by itself and given together with the standard cancer treatments; to check the safety of VIR-5500 when given by itself to people in China and Japan; and to check how well VIR-5500 controls tumors when given by itself and given together with the standard cancer treatments. Adult men with certain types of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types of cancer in this study are: Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow; Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that continues to grow even when testosterone levels are low; and High-risk biochemical recurrent prostate cancer (high-risk BRPC). Biochemical recurrence is a rise in PSA levels after treatment for prostate cancer. Men whose PSA levels double in less than 1 year are considered high risk of the cancer coming back and quickly getting worse. In this study, VIR-5500 will be given to people for the first time. VIR-5500 will either be given itself or given together with at least one of the standard cancer treatments: enzalutamide, darolutamide, and docetaxel. The standard cancer treatment given will depend on which part of the study the men are in, and what type of prostate cancer they have. Other cancer treatments may be given, depending on results from other ongoing studies. The study will have 4 parts. In Part 1, different small groups of men with Metastatic castration-resistant prostate cancer (mCRPC) will receive lower to higher doses of VIR-5500 given by itself. Any medical problems will be recorded for each dose. This is to find out suitable doses to use in Part 2 of the study. In Part 2, other small groups of men with mCRPC will receive the suitable doses of VIR-5500 worked out from Part 1. These men will have previously received specific cancer treatments before starting this study. In Part 3, other different small groups of men with metastatic hormone-sensitive prostate cancer (mHSPC), mCRPC or high-risk BRPC will receive lower to higher doses of VIR-5500 given by itself or given with the other standard cancer treatments. They will be given VIR-5500 with enzalutamide or darolutamide, VIR-5500 with docetaxel, VIR-5500 with docetaxel and enzalutamide, or VIR- 5500 with docetaxel and darolutamide. Any medical problems will be recorded for each dose. This is to find out suitable doses to use in Part 4 of the study. In Part 4, other small groups of men with mHSPC, mCRPC or high-risk biochemical recurrent prostate cancer (BRPC) will receive the suitable doses of VIR-5500 given together with the standard cancer treatments, worked out in Part 3. They will be given VIR-5500 with enzalutamide, VIR-5500 with darolutamide, VIR-5500 with docetaxel and enzalutamide, or VIR-5500 with docetaxel and darolutamide. The standard cancer treatment given will depend on their previous treatment before joining the study and the type of prostate cancer they have.
Conditions
- Hormone-refractory Prostate Cancer
Interventions
VIR-5500Drug
Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
Androgen receptor signaling inhibitor (ARSI)Drug
Oral administration
DocetaxelDrug
Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, 1a, 2a and Part 3: Number of Participants With Adverse Events (AEs) (mCRPC, mHSPC and BRPC)Time frame: Up to 80 months
- Part 1, 1a, 2a and Part 3: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (mCRPC, mHSPC and BRPC)Time frame: Up to 80 months
- Part 1, 1a and Part 3: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Up to 28 Days
- Part 2 and 4: Prostate-Specific Antigen (PSA) Response Rate (PSA50) (mCRPC and mHSPC)Time frame: Up to 80 months
- Part 2 and 4: Objective Response Rate (ORR) (mCRPC and mHSPC)Time frame: Up to 80 months
- Part 4: PSA50 Response Rate (BRPC)Time frame: Up to 80 months
- Part 4: Duration of PSA50 Response (BRPC)Time frame: Up to 80 months
Locations
30 sites in 5 countries. Site status is shown where the registry gives one.
Duarte Cancer Center
Duarte, California · Recruiting
University of California Irvine
Irvine, California · Recruiting
Lennar Foundation Cancer Center
Irvine, California · Recruiting
UCI Health Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
University of California
San Francisco, California · Recruiting
Chicago Cancer Center
Zion, Illinois · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Site AU61002
Darlinghurst, Australia · Recruiting
Site AU61001
Melbourne, Australia · Recruiting
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Site ES34001
Barcelona, Spain · Recruiting
Site ES34007
Barcelona, Spain · Recruiting
Site ES34015
Barcelona, Spain · Withdrawn
Site ES34006
El Palmar, Spain · Recruiting
Site ES34010
Logroño, Spain · Recruiting
Site ES34003
Madrid, Spain · Recruiting
Site ES34008
Madrid, Spain · Recruiting
Site ES34012
Madrid, Spain · Recruiting
Site ES34013
Málaga, Spain · Recruiting
Site ES34004
Pamplona, Spain · Recruiting
Site ES34002
Pozuelo de Alarcón, Spain · Recruiting
Site ES34005
Sabadell, Spain · Recruiting
Site ES34009
Valencia, Spain · Recruiting
Site ES34011
Valencia, Spain · Recruiting
Site GB44003
Leicester, United Kingdom · Recruiting
Site GB44001
London, United Kingdom · Recruiting
Site GB44004
Newcastle, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.